海思科：HSK39297片获临床试验批准

Core Viewpoint - The company received approval from the National Medical Products Administration for clinical trials of its innovative drug HSK39297 tablets, aimed at treating age-related macular degeneration, indicating a significant advancement in its product pipeline [1] Group 1: Drug Development - HSK39297 is a tablet formulation specifically targeting age-related macular degeneration [1] - Preclinical studies have shown that HSK39297 has a clear target, confirmed efficacy, and good safety profile, suggesting a high benefit/risk ratio [1] - The drug is expected to offer a more advantageous treatment option compared to existing therapies, which often require frequent injections and do not significantly improve vision [1] Group 2: Market Potential - There are currently limited treatment options available for age-related macular degeneration, highlighting the potential market opportunity for HSK39297 [1] - The approval for clinical trials positions the company favorably within a niche market with significant unmet medical needs [1]